Phase II Trial of Everolimus or Everolimus Plus Paclitaxel as First-line Therapy in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma: Hoosier Cancer Research Network GU10-147

Trial Profile

Phase II Trial of Everolimus or Everolimus Plus Paclitaxel as First-line Therapy in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma: Hoosier Cancer Research Network GU10-147

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Jul 2017

At a glance

  • Drugs Everolimus (Primary) ; Paclitaxel
  • Indications Bladder cancer; Urethral cancer; Urogenital cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Oct 2017.
    • 19 Jan 2017 Planned End Date changed from 1 Apr 2017 to 1 Apr 2018.
    • 19 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top